Energetics and Glutamate in Schizophrenia

Prior treatment

• Lacking in mental capacity to provide informed consent to study participation.
  • 2\. Diabetes or history of taking an antidiabetic medication 3. Presence of contraindication to MRI at 7 Tesla, including metallic or electronic implants and dental wires.
  • 4\. Severe claustrophobia prohibiting participation on PET or MRI 5. Body size above the comfortable limits for the MRI scanner. 6. Previous participation in research or clinical procedure/s involving ionising radiation, which, including the current study, would result in total radiation exposure \>=10mSv within 12 months 7. History of head injury resulting in loss of consciousness for \> 5 minutes 8. Meeting ICD-11 criteria for organic mental disorder (F00-F09) 9. Meeting ICD-11 criteria for mental and behavioural disorders due to psychoactive substance use (F10-F19) 10. With exclusion of nicotine or cannabis, meeting ICD-11 criteria for psychoactive substance dependence 11. Participation in clinical trial investigating any pharmacological agent other than a licensed antipsychotic compound in the last month.

Other

• All participants:
• Pregnancy or breastfeeding

• Healthy volunteer group:
• 1\. No history of psychiatric illness, as assessed on the Mini neuropsychiatric Interview (MINI).
• Treatment responsive schizophrenia group:
• Meeting ICD-11 criteria for schizophrenia (F20)
• Meeting symptomatic consensus criteria for remission, defined as scores of mild or less on items P1, P2, P3, N1, N4, N6, G5 and G9 of the PANSS and no history of symptomatic relapse in the past 6 months.
• Currently receiving one or more of the following antipsychotic medications: Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone.
• Antipsychotic adherent, defined as having a score of \>=moderate adherence on the Kemp scale.
  • Treatment-resistant schizophrenia group:
• Meeting ICD-11 criteria for schizophrenia (F20)
• Meeting modified consensus criteria for treatment resistance, including history of at least two antipsychotic treatment trials each lasting ≥6 weeks at a dose of ≥400mg chlorpromazine equivalents.
• Total PANSS total score \> 70
• Moderate functional impairment (\<60 on the SOFAS)
• Currently receiving one or more of the following antipsychotic medications: Clozapine; Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone.
• Antipsychotic adherent, defined as having a score of \>=moderate adherence on the Kemp scale.